Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
2967620
Reference Type
Journal Article
Title
Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence
Author(s)
Long, Q; Xu, J; Osunkoya, AO; Sannigrahi, S; Johnson, BA; Zhou, W; Gillespie, T; Park, JY; Nam, RK; Sugar, L; Stanimirovic, A; Seth, AK; Petros, JA; Moreno, CS
Year
2014
Is Peer Reviewed?
Yes
Journal
Cancer Research
ISSN:
0008-5472
EISSN:
1538-7445
Volume
74
Issue
12
Page Numbers
3228-3237
Language
English
PMID
24713434
DOI
10.1158/0008-5472.CAN-13-2699
Abstract
Prostate cancer remains the second leading cause of cancer death in American men and there is an unmet need for biomarkers to identify patients with aggressive disease. In an effort to identify biomarkers of recurrence, we performed global RNA sequencing on 106 formalin-fixed, paraffin-embedded prostatectomy samples from 100 patients at three independent sites, defining a 24-gene signature panel. The 24 genes in this panel function in cell-cycle progression, angiogenesis, hypoxia, apoptosis, PI3K signaling, steroid metabolism, translation, chromatin modification, and transcription. Sixteen genes have been associated with cancer, with five specifically associated with prostate cancer (BTG2, IGFBP3, SIRT1, MXI1, and FDPS). Validation was performed on an independent publicly available dataset of 140 patients, where the new signature panel outperformed markers published previously in terms of predicting biochemical recurrence. Our work also identified differences in gene expression between Gleason pattern 4 + 3 and 3 + 4 tumors, including several genes involved in the epithelial-to-mesenchymal transition and developmental pathways. Overall, this study defines a novel biomarker panel that has the potential to improve the clinical management of prostate cancer.
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity